![]() |
市場調查報告書
商品編碼
2008729
PET-CT掃描儀設備市場報告:按類型、切片數量、同位素/檢測器類型、服務供應商、應用和地區分類,2026-2034年PET-CT Scanner Device Market Report by Type, Slice Count, Isotope and Detector Type, Service Provider, Application, and Region 2026-2034 |
||||||
2025年全球PET-CT掃描儀市場規模達24億美元。 IMARC Group預測,到2034年,該市場規模將達到33億美元,2026年至2034年的複合年成長率為3.33%。推動該市場穩定成長的因素包括:生活方式改變和環境因素導致癌症發病率上升、技術進步提高了影像品質、效率和病患安全性,以及人口老化。
癌症患者數量增加
全球癌症發生率的不斷攀升推動了PET-CT掃描儀市場的成長。 PET-CT掃描儀在癌症診斷、分期和治療過程監測中發揮著至關重要的作用。 PET-CT影像的早期檢測能夠提高治療效果並改善患者預後,因此得到了廣泛應用。此外,醫療專業人員越來越依賴PET- 電腦斷層掃描來進行精準的疾病表徵和製定個人化的治療方案。這些掃描利用癌細胞選擇性吸收的放射性藥物來視覺化腫瘤內的代謝活動。同時, 電腦斷層掃描提供詳細的解剖影像,有助於準確識別PET檢測到的異常代謝活動。 PET- 電腦斷層掃描獲得的全面資訊有助於腫瘤科醫師就治療策略(包括手術、放射線治療、化療和標靶治療)做出明智的決策。此外,PET- 電腦斷層掃描還可以加快治療的啟動速度,從而潛在地改善患者的預後。在對抗癌症的鬥爭中,提高先進診斷工具的可及性至關重要。
技術進步
PET-CT掃描儀的創新有助於提高影像品質、效率和病患安全性。最新的PET-CT掃描儀具有更高的空間解析度,能夠更清晰地顯示微小病灶,並提高腫瘤檢測和定性的準確性。這項進步使得早期診斷和更精準的治療方案製定成為可能。此外,先進的PET-CT掃描儀縮短了掃描時間,最大限度地減少了患者的不適感,並簡化了醫療機構的工作流程。快速影像擷取使臨床醫生能夠在有限的時間內進行更多掃描,從而提高了患者處理能力和資源利用效率。此外,PET-CT技術的進步正推動著新型掃描儀的研發,這些掃描儀能夠在保持診斷影像品質的同時降低輻射曝射量。這些掃描儀透過最大限度地減少患者的輻射暴露,並降低重複影像檢查帶來的長期不良反應風險,從而提高了安全性。此外,採用呼吸門控和運動追蹤等先進運動校正技術的PET-CT掃描器可確保獲得更清晰、無偽影的影像。
老年人口增加
全球人口老化加劇,推動了對PET-CT掃描儀的需求,對市場產生了正面影響。老年人更容易罹患癌症、阿茲海默症、心血管疾病和其他慢性疾病,因此需要能夠準確檢測和監測這些疾病的先進設備。 PET-CT掃描儀可對心臟功能、心肌灌注和心肌活力進行全面評估,從而支持老年患者心血管疾病的診斷和治療。此外,老齡化與神經退化性疾病風險增加有關。 PET-CT成像能夠提供有關腦部代謝、澱粉樣蛋白沉積和神經傳導物質結合的重要訊息,有助於老年人疾病的早期診斷和監測。此外,老年患者通常合併多種疾病,需要進行全面的診斷評估。 PET-CT掃描儀具有多模態影像功能,可在單次掃描中同時評估多個器官系統。這種綜合方法簡化了診斷流程,並有助於臨床醫生更好地管理老年人複雜的健康狀況。
The global PET-CT scanner device market size reached USD 2.4 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 3.3 Billion by 2034, exhibiting a growth rate (CAGR) of 3.33 % during 2026-2034. The market is experiencing stable growth driven by rising prevalence of cancer due to lifestyle changes and environmental factors, increasing technological innovations that are leading to enhanced imaging quality, efficiency, and patient safety, and the growing geriatric population.
Rising prevalence of cancer cases
The increasing prevalence of cancer among the masses around the world is propelling the PET-CT scanner device market growth. PET-CT scanners play a pivotal role in cancer diagnosis, staging, and treatment monitoring. Early detection through PET-CT imaging enhances treatment efficacy and patient outcomes, contributing to its widespread adoption. Moreover, healthcare providers are increasingly relying on PET-CT scans for accurate disease characterization and personalized treatment planning. These scans utilize radiopharmaceuticals that are selectively taken up by cancer cells, allowing for the visualization of metabolic activity within tumors. Meanwhile, CT scans provide detailed anatomical images that help precisely locate abnormal metabolic activity detected by PET. The comprehensive information obtained from PET-CT scans aids oncologists in making informed decisions regarding treatment strategies, including surgery, radiation therapy, chemotherapy, and targeted therapies. In addition, PET-CT scans enable prompt initiation of treatment and potentially improve patient outcomes. There is a rise in the need for improved access to advanced diagnostic tools to fight against cancer.
Technological advancements
Innovations in PET-CT scanners assist in enhancing imaging quality, efficiency, and patient safety. Modern PET-CT scanners feature higher spatial resolution that allows for clearer visualization of small lesions and improved accuracy in tumor detection and characterization. This advancement enables earlier diagnosis and more precise treatment planning. Moreover, advanced PET-CT scanners offer shorter scan times that benefit in reducing patient discomfort and enhancing workflow efficiency in healthcare settings. Rapid image acquisition enables clinicians to perform more scans in a time frame, leading to increased patient throughput and improved resource utilization. Furthermore, advancements in PET-CT technology are leading to the development of scanners with lower radiation doses while maintaining diagnostic image quality. These scanners improve safety and reduce the risk of long-term adverse effects associated with repeated imaging studies by minimizing radiation exposure to patients. Apart from this, PET-CT scanners employed with advanced motion correction techniques, such as respiratory gating and motion tracking, ensure sharper and artifact-free images.
Increasing geriatric population
The growing demand for PET-CT scanner devices due to rising geriatric population worldwide is positively influencing the market. Elderly individuals are more susceptible to cancer, Alzheimer's disease, cardiovascular disorders, and other chronic diseases, necessitating advanced devices that detect and monitor diseases accurately. PET-CT scanners enable comprehensive assessment of cardiac function, myocardial perfusion, and viability, aiding in the diagnosis and management of cardiovascular conditions in geriatric patients. Moreover, aging is associated with an increased risk of neurodegenerative disorders. PET-CT imaging provides valuable insights into brain metabolism, amyloid deposition, and neuroreceptor binding that facilitate early diagnosis and disease monitoring in elderly individuals. Apart from this, geriatric patients often have multiple comorbidities, requiring comprehensive diagnostic evaluations. PET-CT scanners offer multimodal imaging capabilities, allowing for simultaneous assessment of multiple organ systems in a single examination. This integrated approach benefits in streamlining diagnostic workflows and enhancing clinical decision-making in managing complex health conditions in the elderly.
Stationary scanners account for the majority of the market share
Stationary scanners are large and fixed imaging systems that are usually found in hospitals, imaging centers, and academic institutions. They are designed to provide high-resolution imaging for a wide range of applications, including oncology, cardiology, and neurology. They offer superior image quality and diagnostic accuracy. They have comprehensive anatomical and functional imaging capabilities.
Portable scanners/mobile scanners are compact and mobile imaging systems designed for flexible deployment in various clinical settings, including intensive care units (ICUs), operating rooms, and remote locations. They offer on-site imaging capabilities, enabling POC diagnostics and intraoperative imaging during surgical procedures. They are compact and have a lightweight design for easy transportation.
Medium slice scanner (64 slices) holds the largest market share
Medium slice scanner (64 slices) offers enhanced imaging capabilities as compared to low slice scanners and provide higher image resolution, faster scan times, and improved diagnostic accuracy. It is commonly used in larger hospitals, imaging centers, and academic institutions for a wide range of clinical applications. It is suitable for precise tumor localization, staging, and treatment planning. It assists in providing improved image quality and diagnostic accuracy.
Low slice scanner (<64 slices) is suitable for basic imaging applications and commonly found in smaller healthcare facilities, clinics, and outpatient centers where lower throughput and image quality suffice for routine diagnostic purposes. It has basic imaging capabilities for routine diagnostic studies. It is economical and has a space-efficient design suitable for smaller healthcare settings.
High slice scanner (>64 slices) offers advanced imaging performance with ultra-high spatial resolution, rapid scan speeds, and advanced clinical applications. It is used in advanced medical centers, research institutions, and specialized healthcare facilities for demanding imaging studies. It has advanced imaging capabilities for complex clinical and research applications.
Flurodeoxyglucose (FDG) represents the leading market segment
Flurodeoxyglucose (FDG) is commonly used radiotracer in PET imaging. It consists of a glucose molecule labeled with a positron-emitting fluorine-18 (^18F) isotope. FDG is taken up by cells in proportion to their metabolic activity, making it a valuable tool for detecting areas of increased glucose metabolism, such as cancerous tumors. It evaluates brain metabolism and detects various neurodegenerative diseases.
62Cu ATSM is a radiotracer used in PET imaging to assess tissue oxygenation. It selectively accumulates in hypoxic regions of tissues, making it useful for identifying areas of poor oxygenation within tumors. 62Cu ATSM PET imaging has potential applications in oncology for predicting tumor response to therapies and guiding treatment decisions.
FMISO is a radiotracer used in PET imaging to assess tissue hypoxia. It penetrates cell membranes and becomes trapped in hypoxic cells due to reduced oxygen availability. FMISO PET imaging enables visualization and quantification of tissue hypoxia, which is associated with tumor aggressiveness, resistance to therapy, and poor patient outcomes.
Gallium-based radiotracers, such as Ga-DOTA peptides and Ga-PSMA, are used in PET imaging for various clinical applications. Ga-DOTA peptides target somatostatin receptors and are employed in neuroendocrine tumor imaging, while Ga-PSMA targets prostate-specific membrane antigen and is used in prostate cancer imaging.
Hospitals exhibit a clear dominance in the market
Hospitals are healthcare institutions that provide a wide range of medical services, including diagnostic imaging. Hospital-based imaging departments offer comprehensive imaging services to inpatients and outpatients and serve a diverse patient population across various medical specialties and clinical settings. It has multidisciplinary teams of healthcare professionals, including radiologists, oncologists, and nuclear medicine physicians.
Diagnostic centers, also known as imaging centers or medical imaging facilities, specialize in providing diagnostic imaging services to patients referred by healthcare providers. These centers focus on diagnostic imaging and offer a range of imaging modalities, including PET-CT scanners, in outpatient settings. They focus on outpatient care, with no inpatient services provided.
Research institutes are academic or independent organizations dedicated to scientific research and innovation. They have advanced imaging technologies, including PET-CT scanners, to support preclinical and clinical research studies across various disciplines. They focus on scientific research and innovation in specific fields of study.
Oncology dominates the market share
In oncology, PET-CT imaging plays a critical role in the diagnosis, staging, treatment planning, and monitoring of various types of cancers. PET-CT scans help oncologists visualize metabolic activity within tumors, assess tumor characteristics, detect metastases, and evaluate treatment response. These scanners are beneficial in diagnosing and staging cancers, including lung cancer, breast cancer, colorectal cancer, and lymphoma. They are beneficial in early detection of tumors and metastases for timely intervention.
In neurology, PET-CT imaging is utilized to evaluate brain metabolism, assess neurodegenerative diseases, detect brain tumors, and investigate neurological disorders. PET-CT scans provide valuable insights into brain function, neurotransmitter activity, and cerebral blood flow, aiding in the diagnosis and management of various neurological conditions.
In cardiology, PET-CT imaging is used to assess myocardial perfusion, viability, and function, and to detect and characterize coronary artery disease and other cardiac abnormalities. PET-CT scans provide detailed anatomical and functional information, enabling cardiologists to diagnose cardiac conditions, evaluate treatment options, and assess prognosis.
Asia Pacific leads the market, accounting for the largest PET-CT scanner device market share
The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, Asia Pacific accounted for the largest market share due to the presence of well-established new hospitals, diagnostic centers, and specialty clinics. In addition, the rising prevalence of cancer among individuals in the region is bolstering the market growth.
North America stands as another key region in the market, driven by the increasing awareness among individuals about the benefits of early disease detection. Besides this, North America is a hub for technological innovation in healthcare, with leading manufacturers and research institutions continuously developing advanced PET-CT scanner devices.
Europe maintains a strong presence in the market, with the rising focus on improving patient care. Additionally, stringent regulatory standards ensure the safety and efficacy of PET-CT scanner devices, which is impelling the market growth.
Latin America exhibits the growing potential in the market on account of the improving healthcare infrastructure. In addition, the growing demand for advanced care among patients is offering a positive market outlook.
The Middle East and Africa region is primarily driven by the thriving medical tourism. Furthermore, partnerships between local healthcare providers, international medical device manufacturers, and research institutions are facilitating technology transfer and knowledge sharing relayed to PET-CT scanners.
Key players are investing in R&D activities to develop innovative PET-CT scanner technologies with improved imaging capabilities, enhanced diagnostic accuracy, and patient comfort. They are exploring new radiotracers and imaging agents to expand the applications of PET-CT scans in oncology, neurology, cardiology, and other medical specialties. Additionally, they are incorporating advanced technologies to automate image analysis, optimize workflows, and improve diagnostic efficiency. Besides this, major manufacturers are introducing next-generation PET-CT scanner models with advanced features, such as higher image resolution, faster scan times, reduced radiation doses, and enhanced software functionalities. They are also developing compact and mobile PET-CT scanners to improve accessibility and flexibility in various clinical settings, including hospitals, clinics, and remote locations.
The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided. Some of the key players in the market include: